Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00542451 · FLOW

Participant flow

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer · Source last updated 2024-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    80 mg of paclitaxel per square meter of body-surface area weekly for 12 weeks and a loading dose of 4 mg of intravenous trastuzumab per kilogram of body weight on day 1, followed by 2 mg per kilogram weekly, for a total of 12 doses. After the completion of 12 weeks of treatment with Trastuzumab, the dosing of Trastuzumab 6mg/kg over 3 weeks to complete a full year of intravenous treatment with trastuzumab.
    id
    FG000
    title
    Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        31
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        30
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Physician Decision
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Recurrent disease
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      unknown reason
    6. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death
    7. reasons
      1. group Id
        FG000
        num Subjects
        10
      type
      Lost to Follow-up
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        406
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        327
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        79
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    80 mg of paclitaxel per square meter of body-surface area weekly for 12 weeks and a loading dose of 4 mg of intravenous trastuzumab per kilogram of body weight on day 1, followed by 2 mg per kilogram weekly, for a total of 12 doses. After the completion of 12 weeks of treatment with Trastuzumab, the dosing of Trastuzumab 6mg/kg over 3 weeks to complete a full year of intravenous treatment with trastuzumab.
    id
    FG000
    title
    Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        31
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        30
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Physician Decision
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Recurrent disease
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      unknown reason
    6. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Death
    7. reasons
      1. group Id
        FG000
        num Subjects
        10
      type
      Lost to Follow-up
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        406
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        327
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        79
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice